Fibromyalgia and Medicinal Cannabis
DOI:
https://doi.org/10.36557/2674-8169.2024v6n9p2279-2295Keywords:
Fibromyalgia; Clinical Management; Therapeutic Approaches.Abstract
Fibromyalgia is a multisymptomatic syndrome, whose most prevalent symptoms are chronic pain, fatigue, sleep disorders, and depression, resulting in a reduced quality of life. As it is an incurable condition, the treatment of fibromyalgia aims to relieve symptoms through pharmacological and non-pharmacological means. However, due to the limited success of conventional treatment, medicinal cannabis has been considered a therapeutic option to improve symptoms and patient well-being. This review aimed to evaluate the efficacy and adverse effects of fibromyalgia treatment with medicinal cannabis and the obstacles to accessing the product. A search for previous works was conducted on the PubMed and BVS platforms, and a total of 13 scientific articles were included after applying inclusion and exclusion criteria. Through the analyses performed, it was observed that medicinal cannabis significantly improves pain, sleep quality, memory, and depression, leading to reduced medication use and better quality of life for patients. Moreover, the reported side effects of therapeutic cannabis use are generally mild, such as dizziness and drowsiness, indicating good treatment tolerability. However, therapeutic use of cannabis remains a challenge as there are barriers to accessing medication and gaps in the regulation of the production and sale of products. In conclusion, it is crucial to highlight the importance of conducting further research on the long-term effects and tolerability of medicinal cannabis, as well as expanding access to this form of treatment. This article aims to carry out a review of the current medical literature on the relationship between quality of life and satisfaction in users of mucous-supported complete dentures and implant-supported complete dentures. Google Scholar, Scopus and Web of Science indexes were used as search engines for the selection of articles, using the keywords “Quality of life, Satisfaction, Mucus-supported complete denture, Implant-supported complete denture”. It is concluded that users of implant-supported complete dentures have better quality of life and satisfaction with their prostheses, when compared to users of mucous-supported complete dentures.
Downloads
References
AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA – ANVISA. Revisão da RDC no 327/2019 - Participação Social, 2022. Disponível em: https://www.gov.br/anvisa/pt-br/assuntos/educacaoepesquisa/webinar/medicamentos/arquivos/WebinarAIRProdutosCannabiseParticipa.pdf
BERGER, A. A. et al. Cannabis and cannabidiol (CBD) for the treatment of fibromyalgia. Best practice & research. Clinical anaesthesiology, v. 34, n. 3, p. 617–631, 2020.
BOEHNKE, K. F. et al. Cannabidiol Product Dosing and Decision-Making in a National Survey of Individuals with Fibromyalgia. The Journal of Pain, jun. 2021.
BOEHNKE, K. F. et al. Cannabidiol Use for Fibromyalgia: Prevalence of Use and Perceptions of Effectiveness in a Large Online Survey. The Journal of Pain, jan. 2021.
BOEHNKE, K. F. et al. Substituting Cannabidiol for Opioids and Pain Medications Among Individuals With Fibromyalgia: A Large Online Survey. The Journal of Pain, v. 22, n. 11, maio 2021.
BOURKE, S. L. et al. Cannabinoids and the endocannabinoid system in fibromyalgia: A review of preclinical and clinical research. Pharmacology & therapeutics, v. 240, n. 108216, p. 108216, 2022.
BETTSTETTER, H.; SCHÄFER, A. Tetrahydrocannabinol (THC) bei Patienten mit Fibromyalgiesyndrom (FMS): Retrospektive Untersuchung zu Veränderungen von Schmerz, psychometrischen Variablen und Analgetikaverbrauch im Verlauf einer interdisziplinären multimodalen stationären Schmerztherapie (IMST). Schmerz (Berlin, Germany), v. 38, n. 4, p. 259–266, 2024.
CAMERON, E. C.; HEMINGWAY, S. L. Cannabinoids for fibromyalgia pain: a critical review of recent studies (2015–2019). Journal of cannabis research, v. 2, n. 1, 2020.
CHAVES, C.; BITTENCOURT, P. C. T.; PELEGRINI, A. Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Pain Medicine, v. 21, n. 10, p. 2212–2218, 1 out. 2020.
FITZCHARLES, M.-A. et al. Use of medical cannabis by patients with fibromyalgia in Canada after cannabis legalisation: a cross-sectional study. Clinical and Experimental Rheumatology, v. 39, n. 3, p. 115–119, 21 jun. 2021.
GIORGI, V. et al. Adding medical cannabis to standard analgesic treatment for fibromyalgia: a prospective observational study. Clinical and Experimental Rheumatology, v. 38 Suppl 123, n. 1, p. 53–59, 1 jan. 2020.
HABIB, G.; ARTUL, S. Medical Cannabis for the Treatment of Fibromyalgia. Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases, v. 24, n. 5, p. 255–258, 1 ago. 2018.
HERSHKOVICH, O. et al. The role of cannabis in treatment‐resistant fibromyalgia women. Pain Practice, v. 23, n. 2, p. 180–184, 9 nov. 2022.
KHURSHID, H. et al. A systematic review of fibromyalgia and recent advancements in treatment: Is medicinal cannabis a New Hope? Cureus, 2021.
MARTINS, D. DO A.; POSSO, I. DE P. Current legislation on medical cannabis. History, movements, trends and counter-tendencies, in the Brazilian territory. BrJP, v. 6, p. 75–79, 2023.
MASCARENHAS, R. O. et al. Association of therapies with reduced pain and improved quality of life in patients with fibromyalgia: A systematic review and meta-analysis. JAMA internal medicine, v. 181, n. 1, p. 104, 2021.
MAIONE, S.; COSTA, B.; DI MARZO, V. Endocanabinoides: Uma oportunidade única para desenvolver analgésicos multialvo. Pain, v. 154, n. Suplemento 1, p. S87–S93, 2013.
MAZZA, M. Medical cannabis for the treatment of fibromyalgia syndrome: a retrospective, open-label case series. Journal of Cannabis Research, v. 3, n. 1, 17 fev. 2021.
PEREIRA, A. S., SHITSUKA, D. M., PARREIRA, F. J., & SHITSUKA, R. (2018). Metodologia da pesquisa científica [recurso eletrônico] – 1. ed. – Santa Maria, RS: UFSM, NTE.
RUSSO, E. B.; MARCU, J. Cannabis pharmacology: The usual suspects and a few promising leads. Em: Advances in Pharmacology. [s.l.] Elsevier, 2017. p. 67–134.
SAGY, I. et al. Safety and Efficacy of Medical Cannabis in Fibromyalgia. Journal of Clinical Medicine, v. 8, n. 6, p. 807, 5 jun. 2019.
SAVAGE, S. R. et al. Cannabis in pain treatment: Clinical and research considerations. The journal of pain: official journal of the American Pain Society, v. 17, n. 6, p. 654–668, 2016.
SARZI-PUTTINI, P. et al. Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. Nature reviews. Rheumatology, v. 16, n. 11, p. 645–660, 2020.
VAN DE DONK, T. et al. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain, v. 160, n. 4, p. 860–869, 1 abr. 2019.
YASSIN, M.; ORON, A.; ROBINSON, D. Effect of adding medical cannabis to analgesic treatment in patients with low back pain related to fibromyalgia: an observational cross-over single centre study. Clinical and Experimental Rheumatology, v. 37 Suppl 116, n. 1, p. 13–20, 1 jan. 2019.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Milena Andrade Spinelli, Laís de Souza Coutinho, Flavia Avelino Galvão de Moura, Luísa Pereira Ribeiro, Camila Dos Santos Marotta, Helena Lopes Carneiro, Ramon Fraga de Souza Lima
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors are copyright holders under a CCBY 4.0 license.
